Interleukin-17 activates and synergizes with the notch signaling pathway in the progression of pancreatic ductal adenocarcinoma

Interleukin (IL)-17 is a prominent cytokine that promotes pancreatic intraepithelial neoplasia (PanIN) and pancreatic ductal adenocarcinoma (PDAC) and is associated with the oncogenic pathways in tumor progression. However, the mechanism and therapeutic value of the IL-17 axis remain unclear. In thi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer letters 2021-06, Vol.508, p.1-12
Hauptverfasser: Wang, Xianze, Chen, Hao, Jiang, Rui, Hong, Xiafei, Peng, Junya, Chen, Wenyan, Jiang, Jialin, Li, Jie, Huang, Dan, Dai, Hongmei, Wang, Wenze, Lu, Junliang, Zhao, Yupei, Wu, Wenming
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Interleukin (IL)-17 is a prominent cytokine that promotes pancreatic intraepithelial neoplasia (PanIN) and pancreatic ductal adenocarcinoma (PDAC) and is associated with the oncogenic pathways in tumor progression. However, the mechanism and therapeutic value of the IL-17 axis remain unclear. In this study, we verified the activation of the IL-17 and Notch pathways in PanIN/PDAC via complementary approaches and validated their pro-tumor effects on tumor progression. Additionally, we found a positive correlation between IL-17 and Notch; the IL-17 axis can upregulate Notch activity via the canonical NF-κB pathway in vitro, thus synergistically promoting PanIN/PDAC. Furthermore, we observed that the co-inhibition of IL-17 and the Notch pathway can enhance the therapeutic effect by restricting tumor growth in vivo. Our study highlights the synergistic effect of the IL-17 axis and Notch pathway in promoting PanIN/PDAC and further suggests that IL-17-Notch co-inhibition is a novel therapeutic strategy with superior potential in treating PDAC. •This study investigated the activation of the IL-17 and Notch pathways in PanIN/PDAC.•Complementary approaches validated the effects of IL-17-Notch on tumor progression.•IL-17 and Notch pathways are positively correlated, promoting PanIN/PDAC synergy.•The IL-17 axis upregulates Notch activity via the canonical NF-κB pathway in vitro.•The IL-17-Notch co-inhibition can be a novel and potent therapy for PDAC.
ISSN:0304-3835
1872-7980
DOI:10.1016/j.canlet.2021.03.003